Supply of salbutamol (VENTOLIN ROTACAPS) 200mg insufflations strip pack by GlaxoSmithKline Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted to regulate the supply and distribution of therapeutic goods in Australia, was supplemented by a notice dated March 20, 2013, concerning the product salbutamol (VENTOLIN ROTACAPS) 200 mg insufflations strip pack [Aust R 12530] supplied by GlaxoSmithKline Australia Pty Ltd. This notice was issued by the delegate of the Secretary of the Department of Health and Ageing, pursuant to subsections 14 and 14A of the Act. The primary issue addressed by this notice was the non-conformance of the product with the current British Pharmacopoeia monograph requirements for salbutamol powder for inhalation, specifically regarding the deposition of the emitted dose. The consent granted is subject to conditions outlined in subsection 15(1) of the Act and is effective until January 1, 2014, when an updated BP monograph is expected to become official. This exemption is contingent on the information and data provided by the company in their application and related correspondence.

Scope and Application

The Therapeutic Goods Act 1989, specifically under sections 14 and 14A, provides a framework for the regulation of therapeutic goods in Australia, and the 2013 notice pertains to the temporary consent granted for the supply of a specific product that does not fully comply with certain pharmacopoeia requirements. The Act applies to entities such as GlaxoSmithKline Australia Pty Ltd, which is authorised to supply therapeutic goods including medicinal products like salbutamol (VENTOLIN ROTACAPS) 200 mg insufflations strip pack. This consent is provided at the Commonwealth level by the delegate of the Secretary of the Department of Health and Ageing, indicating the federal jurisdiction over therapeutic goods regulation in Australia. The consent is limited to the product mentioned and is effective until January 1, 2014, with specific conditions attached, including adherence to the changes approved within the submission concerning the product's emitted dose and fine particle mass. Notably, the exemption granted is contingent upon the information and data provided by the Company, ensuring compliance with the Act's requirements for therapeutic goods supplied within Australia.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) provides a framework for the regulation of therapeutic goods in Australia. In the context of Section 14 and 14A, the Act allows for certain exemptions or special provisions to be made in specific circumstances. In this instance, Section 14(a) of the Act has been invoked to permit the supply of a particular product, salbutamol (VENTOLIN ROTACAPS) 200 mg insufflations strip pack, by GlaxoSmithKline Australia Pty Ltd, despite it not conforming to the current British Pharmacopoeia (BP) monograph requirements for salbutamol powder for inhalation. This exemption is specifically in relation to the deposition of the emitted dose. This is an important provision, as it allows for the continued supply of therapeutic goods that may not fully meet all regulatory standards but are deemed acceptable under specific conditions. Under the Act, the delegate of the Secretary of the Department of Health and Ageing has the authority to grant such exemptions, subject to certain conditions. In this case, the consent is granted with the condition that it applies until January 1, 2014. This date is significant as it aligns with the expected update of the BP monograph, which will presumably address the current non-compliance issues. Furthermore, no other changes to the product have been made apart from those related to the deposition of emitted dose and fine particle mass, which were approved within the submission. This demonstrates a controlled approach to the exemption, ensuring that only specified aspects are adjusted. The obligations imposed by this Act on the governing parties include a rigorous review process for applications to ensure that any exemptions granted are justified and do not compromise public health. GlaxoSmithKline Australia Pty Ltd must adhere to the stipulated conditions of the exemption, which include maintaining the product specifications as outlined in the approval and ensuring compliance with all other regulatory requirements. Additionally, the Department of Health and Ageing must monitor the product’s performance and compliance during the exemption period, ready to take further action if necessary. Any breach of the conditions set by the Act, or failure to comply with the regulatory requirements, can lead to significant consequences. The Act provides for both civil and criminal penalties for non-compliance. The exact penalties depend on the severity and nature of the breach but can include substantial fines, legal action, and, in severe cases, imprisonment. The maximum penalties for offences under the Therapeutic Goods Act can be substantial, reflecting the importance of ensuring the safety and efficacy of therapeutic goods in Australia. Therefore, compliance with the Act is not only a legal requirement but also a critical component of public health protection.